Cortisol And Bone Health Research

---

Table of Contents

1. What Is the Cortisol–Bone Connection?
2. How Cortisol Damages Bone at the Cellular Level
3. Key Clinical Research: Decades of Evidence
4. Subclinical Hypercortisolism and Bone Risk
5. Which Bones Are Most Vulnerable?
6. HPA Axis Dysregulation and Skeletal Consequences
7. Common Questions Answered by the Research
8. Testing Cortisol to Assess Bone Risk
9. Reversibility: Can You Rebuild Bone After Cortisol Damage?
10. Treatment Strategies When Cortisol Is Elevated
11. Summary and Takeaways

---

Introduction

Most people know cortisol as the "stress hormone." Fewer people know that it is one of the most extensively studied chemical threats to the human skeleton. Over the past three decades, researchers have built a compelling, detailed, and at times alarming body of evidence connecting elevated cortisol — whether from chronic stress, adrenal tumors, or glucocorticoid medications — to accelerated bone loss, deteriorating bone microarchitecture, and increased fracture risk.

The field of cortisol and bone health research has moved far beyond simply documenting that Cushing's syndrome patients get osteoporosis. Today, scientists are asking harder, more nuanced questions: Does the normal day-to-day variation in cortisol matter for bone density in otherwise healthy people? Does subclinical, below-the-diagnostic-threshold cortisol excess quietly erode bone over years? Can a 2025 Mendelian randomization study tell us whether the relationship is genuinely causal, and not merely correlational?

This comprehensive post walks through the science layer by layer — from molecular mechanisms in osteoblasts to population cohort data to the latest 2024–2026 reviews — to give you the most complete picture currently available.

---

What Is the Cortisol–Bone Connection?

How Cortisol Damages Bone at the Cellular Level

Key Clinical Research: Decades of Evidence

Subclinical Hypercortisolism and Bone Risk

Which Bones Are Most Vulnerable?

HPA Axis Dysregulation and Skeletal Consequences

Common Questions Answered by the Research

Testing Cortisol to Assess Bone Risk

Reversibility: Can You Rebuild Bone After Cortisol Damage?

Treatment Strategies When Cortisol Is Elevated

Summary and Takeaways

---

(Full section content follows below — the anchored headings above serve as TOC targets; the complete prose for each section continues in order.)

---

What Is the Cortisol–Bone Connection?

Cortisol is a glucocorticoid steroid hormone produced by the adrenal cortex in response to signals from the hypothalamic–pituitary–adrenal (HPA) axis. Its primary evolutionary role is to mobilize energy during stress — raising blood glucose, suppressing inflammation, and directing metabolic resources away from long-term maintenance functions. That last point is critical: under chronic cortisol exposure, "long-term maintenance" includes building and preserving bone.

Cortisol bone health effects have been recognized clinically since Harvey Cushing first described his eponymous syndrome in 1912, noting that patients with extreme cortisol excess developed brittle, fracture-prone skeletons. What has changed in the decades since is the resolution at which researchers can study the relationship. We now know that even modest, physiologically "normal" elevations in cortisol — the kind produced by chronic psychological stress, disrupted sleep, or subtle autonomous adrenal cortisol secretion — can meaningfully impair bone density and structure over time.

The cortisol skeletal research literature broadly divides into three exposure categories:

1. Endogenous pathological excess — Cushing's syndrome or disease, where cortisol is dramatically elevated
2. Exogenous glucocorticoid exposure — patients taking prednisone, dexamethasone, or inhaled corticosteroids for inflammatory conditions
3. Subclinical or physiological variation — normal-to-high-normal cortisol in the general population, aging adults, or individuals with chronic stress

This post focuses primarily on the second and third categories, where the evidence is most directly relevant to the largest number of people, and where the most interesting recent research has emerged.

---

How Cortisol Damages Bone at the Cellular Level

To understand the data that follows, it helps to understand the cellular machinery that cortisol disrupts. Bone is not an inert structure — it is continuously remodeled by a tightly regulated interplay between two cell types: osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). Healthy bone requires these two populations to remain in balance.

The Cortisol–Osteoblast Problem

The cortisol osteoblast relationship is one of the most thoroughly characterized aspects of glucocorticoid bone biology. Glucocorticoids act through intracellular glucocorticoid receptors (GRs) that are abundantly expressed in osteoblast lineage cells. When cortisol binds these receptors, the consequences for osteoblasts are harmful in multiple ways:

• Suppressed differentiation: Cortisol impairs the commitment of mesenchymal stem cells to the osteoblast lineage, diverting them instead toward adipocyte differentiation. This means fewer new osteoblasts are generated to replace older ones.
• Reduced lifespan: Glucocorticoids accelerate osteoblast apoptosis (programmed cell death), shrinking the population of active bone-forming cells.
• Impaired collagen synthesis: Osteoblasts produce type I collagen, the structural scaffold upon which mineral is deposited. Cortisol suppresses collagen gene expression, weakening the organic matrix of bone even before mineral density changes are detectable on a DEXA scan.
• Decreased IGF-1 and Wnt signaling: Cortisol interferes with insulin-like growth factor 1 (IGF-1) and Wnt/β-catenin pathways — two of the most important pro-anabolic signaling routes for bone formation.

Cortisol Bone Resorption: The Osteoclast Side

Cortisol bone resorption is driven through equally well-documented mechanisms. Glucocorticoids upregulate RANKL (receptor activator of nuclear factor kappa-B ligand) expression on osteoblasts and T-cells, while simultaneously suppressing osteoprotegerin (OPG) — the natural RANKL inhibitor. The net effect is a shift in the RANKL/OPG ratio that strongly favors osteoclast activation and survival.

This dual mechanism — suppressed bone formation, enhanced bone resorption — creates an uncoupling of the normal remodeling cycle that is particularly destructive. Even a period of months of elevated cortisol can produce measurable changes in bone turnover markers, and over years, this uncoupling translates to structural deterioration that goes beyond simple density loss.

Cortisol, Calcium, and Vitamin D

Cortisol calcium bone interactions add another layer of complexity. Glucocorticoids impair intestinal calcium absorption by antagonizing the effects of vitamin D at the level of intestinal epithelial cells. They also increase renal calcium excretion, reducing the amount of calcium available for bone mineralization. The resulting secondary hyperparathyroidism — where parathyroid hormone rises to compensate for low serum calcium — then further stimulates osteoclast activity, compounding the direct effects of cortisol on bone cells.

This calcium-mediated pathway explains why some of the most effective interventions in glucocorticoid osteoporosis — including the clinical guidelines — emphasize calcium and vitamin D supplementation as a baseline protective strategy, even when other therapies are added.

---

---

Key Clinical Research: Decades of Evidence

The body of cortisol bone loss research spans more than three decades of human studies, ranging from small cross-sectional analyses to large population cohorts to, most recently, Mendelian randomization designs that attempt to establish causality. Here is a structured walk through the most important findings.

1999: Cortisol Profiles in Healthy Elderly Men

One of the early landmark studies asking whether physiological cortisol variation — not pathological excess — matters for bone appeared in a 1999 PubMed publication examining profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men.

The key findings from this study were subtle but important:

• Integrated cortisol across the diurnal cycle showed a weak but statistically meaningful negative association with lumbar spine BMD
• More strikingly, trough cortisol — the lowest cortisol levels in the daily cycle, typically occurring in the evening — was positively associated with the rate of bone loss over a four-year follow-up period, affecting the lumbar spine, femoral neck, and trochanteric region

This trough cortisol finding is mechanistically interesting because it suggests that even the partial nocturnal recovery from cortisol suppression matters. In individuals whose cortisol never drops to appropriately low nighttime levels — a pattern associated with chronic stress and HPA dysregulation — bone is losing its window of relative anabolic recovery.

2005: Cortisol and Rate of Bone Loss in a Population-Based Cohort

The 2005 cohort study published on PubMed, specifically examining cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women, extended these findings to a larger sample and demonstrated important sex differences.

In men, elevated peak plasma cortisol was associated with:

• Faster lumbar spine bone loss over the study period

In women, the picture was somewhat different:

• Elevated peak plasma cortisol was associated with lower femoral neck BMD at baseline
• And with a greater femoral neck loss rate over follow-up

The sex-specific patterns here are clinically meaningful. Women's greater fracture vulnerability at the hip may be partly explained by cortisol's disproportionate effect on femoral neck bone density in this population — a site where fractures carry devastating consequences in older adults.

2012: The Multi-Measure Cortisol BMD Study

The 2012 PubMed study titled "Cortisol secretion, bone health, and bone loss" is one of the most cited pieces of cortisol bone density research because it used multiple cortisol measurement modalities — 24-hour urinary free cortisol, morning serum cortisol, and midnight salivary cortisol — and examined multiple skeletal sites.

The results were striking in their consistency:

• Lumbar BMD was inversely correlated with 24-hour urinary free cortisol (P<0.005) and morning serum cortisol (P<0.05)
• Total femur and femoral neck BMD were also inversely correlated with morning serum cortisol
• Heel ultrasound stiffness index — a measure of bone quality distinct from density — was inversely correlated with midnight salivary cortisol (P<0.005)

The midnight salivary cortisol finding is particularly notable. Midnight salivary cortisol is the test most sensitive to early or mild hypercortisolism and is elevated in subclinical adrenal autonomy. The fact that it was independently associated with worse heel ultrasound bone quality — at a P-value below 0.005 — suggests that even modestly elevated late-night cortisol carries measurable skeletal consequences.

This study also demonstrated that the relationship exists across different parts of the skeleton, across different ways of measuring cortisol, and that no single test captures the full picture.

2025: Mendelian Randomization and Causal Evidence

The most methodologically sophisticated recent contribution to glucocorticoid bone research is the 2025 PubMed study using Mendelian randomization (MR) to examine the impact of mild cortisol excess on osteoporosis and the mediating role of sarcopenia-related traits.

Mendelian randomization uses genetic variants as instrumental variables to approximate the conditions of a randomized controlled trial in observational data. Because genetic variants are assigned at conception and are not subject to confounding in the same way that measured cortisol levels are, MR studies can provide stronger causal inference than traditional cohort analyses.

The findings showed site-specific associations between genetically predicted cortisol excess and osteoporosis risk:

| Skeletal Site | Odds Ratio (OR) | Direction | |---|---|---| | Femoral neck | 0.874 | Protective at some alleles / complex | | Lumbar spine | 1.140 | Increased risk | | Heel (calcaneus) | 1.027 | Modestly increased risk |

The lumbar spine OR of 1.140 indicates a meaningful increase in osteoporosis risk attributable to genetically predicted mild cortisol excess — and notably, this association was partially mediated through sarcopenia-related traits, suggesting that cortisol's effect on muscle mass (leading to reduced mechanical loading of bone) contributes to the skeletal damage alongside its direct cellular effects.

This MR study represents the current frontier of cortisol bone density research in terms of causal evidence, and its findings are largely consistent with the observational literature built over the previous two and a half decades.

---

Subclinical Hypercortisolism and Bone Risk

Subclinical hypercortisolism — also called mild autonomous cortisol secretion (MACS) — is a condition in which adrenal adenomas produce modest amounts of excess cortisol that do not meet the diagnostic criteria for overt Cushing's syndrome. These individuals do not have the classic Cushingoid features (moon face, buffalo hump, purple striae) but they have measurably blunted cortisol suppression after the standard 1-mg overnight dexamethasone suppression test.

The 2024 PMC review titled "Unveiling the Hidden Impact: Subclinical Hypercortisolism and Its Subtle Influence on Bone Health" represents one of the most thorough recent summaries of what happens to bone in this population. The review drew on a growing body of evidence to conclude that:

• 64% to 100% of individuals with increased cortisol levels — even subclinical levels — experience impaired bone health, depending on the population studied and the bone outcome measured
• Prolonged mild cortisol elevation is associated with trabecular bone loss, which affects the microarchitecture of cancellous bone in ways that are not fully captured by standard DEXA density measurements
• Subclinical hypercortisolism raises vertebral fracture susceptibility, and importantly, vertebral fractures in this population frequently occur at bone density levels that would not traditionally be classified as osteoporotic — meaning the fracture risk exceeds what DEXA alone would predict
• Elevated cortisol alters bone microstructure by preferentially destroying the trabecular network, reducing connectivity and increasing porosity in ways that dramatically weaken bone's load-bearing capacity without proportionate BMD changes

The implication is sobering: millions of individuals with adrenal incidentalomas (adrenal tumors found incidentally on imaging, affecting approximately 2–8% of the adult population and increasing with age) may have subclinical cortisol excess that is silently damaging their skeletons. Many of these individuals are never evaluated for bone health consequences.

The 2026 update to the Oxford University Press review "Glucocorticoids and Bone" — covering both endogenous and exogenous glucocorticoid exposure — reinforces this concern, summarizing that even mildly elevated circulating glucocorticoids substantially harm bone and that autonomous cortisol production is now recognized as a significant contributor to spine fracture risk in older adults.

Why Subclinical Cases Matter So Much

The public health significance of subclinical hypercortisolism in the context of glucocorticoid osteoporosis is substantial for several reasons:

1. It is common: Population estimates suggest subclinical cortisol excess affects a meaningful proportion of adults over 50 with adrenal incidentalomas
2. It is underdiagnosed: Without systematic screening, most cases are missed
3. It is modifiable: Surgical removal of the adenoma (adrenalectomy) has been shown in multiple studies to improve bone density and reduce fracture risk
4. Standard fracture risk tools may underestimate risk: FRAX and similar tools do not account for subtle cortisol excess unless a formal Cushing's diagnosis is entered

---

Which Bones Are Most Vulnerable?

A recurring theme across the cortisol skeletal research literature is that the skeleton does not lose bone uniformly under glucocorticoid excess. The distribution of bone loss reflects the underlying biology.

Trabecular Bone: The Primary Target

Trabecular (cancellous) bone — the spongy, lattice-like bone found in vertebral bodies, the femoral neck, the distal radius, and the calcaneus — is disproportionately affected by glucocorticoid exposure. This is because:

• Trabecular bone has a much higher surface-area-to-volume ratio than cortical bone, exposing more bone surface to resorptive osteoclasts
• Trabecular bone turns over much more rapidly, meaning the uncoupling of formation and resorption caused by cortisol has more opportunity to cause net loss
• Osteocyte density is higher in trabecular bone, and osteocyte apoptosis induced by glucocorticoids (a documented mechanism) impairs the bone's ability to detect and repair microdamage

The vertebral bodies, being composed predominantly of trabecular bone, are consequently the most severely affected site in glucocorticoid osteoporosis. Vertebral fractures — which can occur with minimal or no trauma, sometimes simply from the load of the body's own weight — are the most common fracture type in glucocorticoid-exposed individuals.

The Lumbar Spine

Across the cohort studies reviewed above, lumbar spine BMD was consistently and most strongly associated with cortisol measures. The 2012 study found significant inverse correlations between lumbar BMD and both 24-hour urinary free cortisol and morning serum cortisol. The 2005 cohort found faster lumbar bone loss in men with higher peak cortisol. The 2025 Mendelian randomization showed the highest OR for lumbar spine osteoporosis risk (1.140) among the sites studied.

The Femoral Neck and Hip

The femoral neck — the narrow connecting section of bone between the femoral head and shaft — is the site of the most clinically devastating fractures in older adults. While somewhat more cortical in composition than vertebral bodies, the femoral neck still has substantial trabecular content and is clearly affected by cortisol.

The 2005 cohort found that elevated peak cortisol was associated with lower femoral neck BMD and greater femoral neck loss rate in women. The 2012 study found inverse correlations between femoral neck BMD and morning cortisol. The 2025 MR study reported a femoral neck OR of 0.874, which is more complex to interpret — the directionality at the femoral neck appeared partially protective with some cortisol-related genetic variants, suggesting the relationship at this site may be more heterogeneous or subject to confounding by other hormonally linked traits.

The Heel (Calcaneus)

The calcaneus is an interesting measurement site in this literature. Because it is composed of largely trabecular bone and bears significant mechanical load, quantitative ultrasound (QUS) of the heel provides information about bone quality — density, stiffness, and microarchitecture — that complements DEXA. The 2012 study's finding that midnight salivary cortisol was inversely correlated with heel ultrasound stiffness (P<0.005) adds a bone quality dimension to the cortisol-bone relationship that standard DEXA studies may miss.

---

---

HPA Axis Dysregulation and Skeletal Consequences

The HPA bone relationship extends beyond simply measuring cortisol levels. The hypothalamic–pituitary–adrenal axis operates as a dynamic feedback system, and different patterns of HPA dysregulation have different implications for bone health.

Diurnal Rhythm Disruption

Under normal physiology, cortisol follows a pronounced diurnal rhythm: it peaks shortly after waking (the "cortisol awakening response"), declines through the morning, reaches low levels in the afternoon, and hits its nadir around midnight. This rhythm is important for bone because bone formation is somewhat cyclically regulated, and the overnight trough — when cortisol is at its lowest — may represent a window of relative anabolic opportunity for bone.

Several disruptions to this rhythm are relevant:

Blunted diurnal decline: In chronic stress, depression, and sleep disorders, cortisol levels in the afternoon and evening remain higher than normal. The 1999 study's finding that trough cortisol was associated with bone loss rate suggests that this flattening of the diurnal curve is harmful even when peak cortisol appears normal.

Elevated midnight cortisol: The midnight salivary cortisol is the most sensitive early indicator of autonomous adrenal cortisol secretion. Its association with heel bone quality in the 2012 study, and its use as a diagnostic test for subclinical hypercortisolism, highlights that the nocturnal component of cortisol exposure is particularly meaningful for bone.

Cortisol awakening response (CAR) abnormalities: Both blunted and exaggerated CARs have been associated with various health outcomes, though the specific implications for bone in clinical populations remain an active area of research.

Allostatic Load and Chronic Stress

The concept of allostatic load — the cumulative physiological burden of chronic stress adaptation — includes HPA dysregulation as a core component. In populations experiencing chronic psychological or socioeconomic stress, the pattern of mildly but persistently elevated cortisol may represent exactly the kind of sustained low-grade glucocorticoid exposure that the 2024 subclinical hypercortisolism review identifies as harmful to bone microstructure and trabecular integrity.

This creates an important and underappreciated pathway by which chronic psychosocial stress — entirely apart from its behavioral correlates like poor diet and reduced exercise — may directly damage bone through cortisol-mediated mechanisms. The HPA bone relationship is thus not confined to the endocrinology clinic: it is relevant to the primary care, psychiatry, and public health context as well.

ACTH vs. Direct Cortisol Effects

In primary adrenal Cushing's syndrome, ACTH is suppressed while cortisol is elevated. In ACTH-dependent Cushing's disease (pituitary origin), both ACTH and cortisol are elevated. This distinction matters for bone because ACTH itself has direct effects on bone cells — including promoting osteoblast survival and function through melanocortin receptors. When ACTH is suppressed (as in adrenal adenomas, or in patients taking exogenous glucocorticoids), this direct anabolic ACTH signal is lost simultaneously with the rise in cortisol-induced bone loss, potentially worsening the net skeletal outcome.

This partly explains why glucocorticoid bone research consistently shows that exogenous glucocorticoid treatment produces some of the fastest and most severe bone loss — the combination of direct cortisol toxicity to osteoblasts and loss of ACTH's trophic bone effects creates a doubly unfavorable environment.

---

Common Questions Answered by the Research

Can high cortisol cause osteoporosis or osteopenia?

Yes — this is one of the most robustly supported relationships in metabolic bone disease. Overt Cushing's syndrome produces some of the fastest rates of bone loss seen in any condition, with many patients progressing to osteoporosis within 1–2 years of onset. Exogenous glucocorticoid-induced osteoporosis (GIOP) affects an estimated 30–50% of patients on long-term oral glucocorticoids. Even subthreshold elevations now show meaningful associations with reduced BMD and increased fracture risk in multiple study designs.

Does stress-related cortisol meaningfully reduce bone density?

The honest scientific answer is: the evidence suggests yes, though the effect size from psychological-stress-level cortisol elevations is smaller than from pathological excess. The population cohort studies from 1999, 2005, and 2012 all found significant inverse associations between cortisol measures and bone density in individuals without overt Cushing's syndrome. The cortisol elevations in these studies were in the physiological range, reflecting the kind of variation seen in chronically stressed or aging individuals.

What cortisol tests are used to assess bone risk?

The research literature has used:

• 24-hour urinary free cortisol (UFC): Integrates total daily cortisol production; the 2012 study found it was the most strongly associated with lumbar BMD
• Morning serum cortisol: A standard, practical measurement; associated with femoral BMD and lumbar BMD in the 2012 study
• Midnight salivary cortisol: Most sensitive to subclinical autonomous secretion; associated with heel bone quality; typically collected by the patient at home
• 1-mg overnight dexamethasone suppression test (DST): Standard screen for subclinical hypercortisolism; post-DST cortisol above 1.8 µg/dL suggests autonomous secretion

In clinical practice, the DST is the most common screening tool for subclinical adrenal cortisol excess, often used in patients with known adrenal incidentalomas. The midnight salivary cortisol is increasingly favored for its sensitivity and ease of collection.

Is bone loss from cortisol reversible?

Partially, and it depends on duration and severity of exposure. The evidence for recovery is most robust in the surgical literature: patients undergoing adrenalectomy for Cushing's syndrome or subclinical hypercortisolism typically show significant BMD gains in the 12–36 months following surgery, though full recovery to age-matched normal density is not always achieved — particularly in sites of predominantly trabecular bone where microarchitectural destruction may be irreversible. For exogenous glucocorticoid-induced osteoporosis, dose reduction or discontinuation is associated with partial BMD recovery, especially at cortical sites.

Which bones are most affected by cortisol excess?

As detailed in the section above, trabecular-rich sites are most vulnerable. In rank order of clinical significance: vertebral bodies (highest risk of fracture with least trauma), femoral neck (highest consequence of fracture), distal radius and calcaneus (significant trabecular content, often measurably affected early).

Does mild or subclinical hypercortisolism matter for fracture risk?

Yes. The 2024 PMC review cited statistics of 64–100% prevalence of impaired bone health in individuals with subclinical cortisol excess, and specifically noted that vertebral fractures occur at BMD levels that would not conventionally be classified as osteoporotic. This "BMD-fracture risk dissociation" is one of the most clinically important features of glucocorticoid-related bone disease.

How does cortisol affect osteoblasts and osteoclasts?

As detailed in the cellular mechanisms section: cortisol suppresses osteoblast differentiation, accelerates osteoblast apoptosis, impairs collagen synthesis, and disrupts pro-anabolic signaling (Wnt, IGF-1). Simultaneously, it shifts the RANKL/OPG ratio to favor osteoclast activation and survival. The net effect is a profound uncoupling of bone remodeling — less formation, more resorption.

Can normal-range cortisol still affect bone health in older adults?

The research suggests yes. The 1999, 2005, and 2012 studies were all conducted in populations without overt Cushing's syndrome, and they found significant inverse associations between cortisol and BMD or bone loss rates. Older adults appear to be particularly vulnerable, possibly because their cortisol levels tend to be somewhat higher (due to age-related HPA changes), their bone remodeling is already shifted toward net loss, and their calcium/vitamin D absorption is already compromised.

What symptoms suggest cortisol-related bone loss?

By the time bone loss is severe enough to cause symptoms, it has typically been occurring for years. Warning signs include:

• Back pain from vertebral compression fractures (often presenting as sudden, localized thoracic or lumbar pain)
• Height loss (from multiple subclinical vertebral fractures)
• Increasing kyphosis ("dowager's hump")
• Fractures from low-impact trauma
• Other features of hypercortisolism: weight gain, fatigue, easy bruising, skin thinning, hypertension, glucose intolerance

What treatments reduce bone risk when cortisol is elevated?

See the full section below. Briefly: treating the underlying cortisol excess (surgical, if applicable); calcium and vitamin D supplementation; bisphosphonates or other antiresorptive therapy; fall prevention; and monitoring with serial DEXA.

---

Testing Cortisol to Assess Bone Risk

The cortisol bone density research field has consistently demonstrated that different cortisol tests capture different aspects of exposure, and no single test is comprehensive. Understanding when and how to use each test is important for clinicians managing patients at risk.

The 1-mg Overnight Dexamethasone Suppression Test

This remains the most commonly used screening tool for subclinical cortisol excess. The patient takes 1 mg of dexamethasone at 11 PM; a morning cortisol above 1.8 µg/dL (50 nmol/L) indicates non-suppression, suggesting autonomous adrenal cortisol production. A threshold of 1.8 µg/dL has high sensitivity (around 95%) but lower specificity — many positives are false positives requiring further workup. A cut-off of 5 µg/dL has higher specificity and is sometimes used in research settings to define "probable" subclinical Cushing's.

In patients with adrenal incidentalomas — the primary population being screened — guidelines recommend this test at baseline with follow-up testing if initial results suggest autonomy.

24-Hour Urinary Free Cortisol

UFC measures total integrated cortisol production over 24 hours. It is most useful for detecting overt hypercortisolism but the 2012 cortisol bone density research study found it was also the most strongly correlated cortisol measure with lumbar BMD even in a non-Cushing's population (P<0.005). It requires complete urine collection, which introduces compliance variability.

Morning Serum Cortisol

Morning cortisol (collected between 8–9 AM, at the diurnal peak) is the most practically accessible test. Its inverse associations with femoral and lumbar BMD in the 2012 study confirm its clinical utility for bone risk assessment.

Midnight Salivary Cortisol

Collected by the patient at home at or near midnight, this test exploits the fact that cortisol should be at its lowest at this time. Any elevation suggests loss of normal diurnal suppression — a hallmark of autonomous cortisol secretion. Its association with heel bone quality in the 2012 study (P<0.005) and its use as a sensitive screening tool for subclinical hypercortisolism make it particularly relevant to bone health assessment.

Patients collect saliva in a provided tube at midnight (the moment of waking from sleep is acceptable) and mail it to a laboratory. Most major endocrinology centers now offer this test.

Integrating Cortisol Testing With DEXA

For patients at elevated cortisol risk, bone health assessment should include:

1. Baseline DEXA of lumbar spine and bilateral hip
2. Vertebral fracture assessment (VFA) — many DEXA machines can image the spine to detect asymptomatic vertebral fractures
3. Fracture risk assessment (FRAX) — though its cortisol-specific modifications are limited
4. Consideration of high-resolution peripheral quantitative CT (HR-pQCT) in research or specialized clinical settings, for trabecular microarchitecture assessment

---

Reversibility: Can You Rebuild Bone After Cortisol Damage?

One of the most clinically important questions in cortisol bone loss research is whether the damage is reversible. The answer requires distinguishing between different types of bone damage.

Bone Density Recovery

BMD recovery following correction of cortisol excess is well-documented in the surgical literature. In patients who undergo successful adrenalectomy for Cushing's syndrome:

• Lumbar spine BMD typically improves by 5–15% in the first 1–2 years post-surgery
• Femoral neck BMD also improves, though typically more slowly
• Recovery is most rapid in younger patients with shorter duration of exposure

In subclinical hypercortisolism, the post-adrenalectomy BMD gains are smaller but still clinically meaningful, and several studies have shown reductions in vertebral fracture incidence following surgical treatment.

Microarchitectural Recovery

The more concerning question is whether trabecular microarchitecture — the three-dimensional lattice structure of cancellous bone — can be restored. The evidence here is less optimistic. High-resolution imaging studies suggest that once trabecular connections (struts) are broken, they do not fully regenerate even with BMD recovery. This is why fracture risk may remain elevated even when DEXA scores improve — the skeleton's structural quality has been permanently compromised in its microarchitectural blueprint.

Pharmacological Bone Recovery

In patients who cannot have their cortisol source removed (or in those on essential long-term glucocorticoid therapy), pharmacological bone protection is the primary strategy:

• Bisphosphonates (alendronate, risedronate, zoledronic acid) inhibit osteoclast activity and are first-line in glucocorticoid osteoporosis. Clinical trials in GIOP have shown 4–8% lumbar spine BMD gains over 1–3 years with bisphosphonate therapy.
• Teriparatide (recombinant PTH 1-34): An anabolic agent that directly stimulates osteoblast activity. In GIOP, teriparatide has been shown in head-to-head trials to produce superior BMD gains compared to bisphosphonates, and with greater fracture risk reduction. It is particularly valuable when the primary problem is suppressed bone formation.
• Denosumab: A monoclonal antibody against RANKL, highly effective in reducing osteoclast activity. Increasingly used in GIOP, particularly in patients who cannot tolerate bisphosphonates.

Exogenous Glucocorticoid Reduction

For patients taking glucocorticoids medically, dose reduction or the use of inhaled (rather than systemic) forms when clinically appropriate provides meaningful bone protection. Some patients can also be transitioned to alternate-day dosing, which may partially preserve HPA axis function and reduce cumulative bone exposure.

---

---

Treatment Strategies When Cortisol Is Elevated

Managing bone health in the context of elevated cortisol requires a tiered approach that addresses both the underlying cortisol excess and its skeletal consequences.

Step 1: Treat the Source of Cortisol Excess Where Possible

For endogenous cortisol excess:

• Adrenal adenoma causing subclinical or overt hypercortisolism: Laparoscopic unilateral adrenalectomy is generally recommended and is associated with BMD improvements and reduced fracture rates
• Cushing's disease (pituitary): Transsphenoidal pituitary surgery is first-line; steroidogenesis inhibitors (metyrapone, ketoconazole, osilodrostat, levoketoconazole) are used when surgery fails or is not feasible
• Adrenal carcinoma or ectopic ACTH: More complex management, often including medical cortisol blockade

For exogenous glucocorticoid use:

• Use the lowest effective dose for the shortest effective time
• Consider inhaled, topical, or intra-articular routes over systemic when clinically appropriate
• Discuss steroid-sparing agents with the prescribing specialist

Step 2: Universal Supplementation

Regardless of the cortisol source, the following should be initiated in any patient with meaningful cortisol excess:

• Calcium: 1,000–1,200 mg daily (dietary preferred; supplemental if dietary intake is inadequate)
• Vitamin D: Sufficient to maintain serum 25-hydroxyvitamin D above 30 ng/mL; typical supplemental doses range from 1,000–2,000 IU/day; higher doses may be needed given glucocorticoid-induced vitamin D resistance at the intestinal epithelium

Step 3: Antiresorptive or Anabolic Pharmacotherapy

The American College of Rheumatology and Endocrine Society both have guidelines for glucocorticoid-induced osteoporosis. Key decision points:

• If the patient is initiating high-dose glucocorticoids (≥7.5 mg/day prednisone equivalent) and has moderate-high fracture risk: initiate pharmacotherapy concurrently with glucocorticoid treatment
• Bisphosphonates (oral or intravenous) are first-line for most patients
• Teriparatide is preferred in patients with very high fracture risk, prior vertebral fractures, or marked suppression of bone formation markers
• Annual DEXA monitoring is recommended during active glucocorticoid therapy

Step 4: Bone Quality and Fall Risk

Given that glucocorticoid excess impairs muscle function (sarcopenia — which the 2025 MR study identified as a mediating pathway), fall risk is elevated independently of bone density. Treatment should address:

• Muscle-strengthening exercise: Weight-bearing and resistance exercise partially offset glucocorticoid-induced muscle and bone loss
• Fall prevention: Environmental modifications, physical therapy, balance training
• Protein intake: Adequate protein supports both muscle mass and bone matrix

Step 5: Monitoring

• DEXA scan every 1–2 years in patients with ongoing glucocorticoid exposure
• Vertebral fracture assessment at baseline and when significant height loss or back pain occurs
• Bone turnover markers (CTX for resorption, P1NP for formation) can guide therapy selection and monitor treatment response

---

---

Summary and Takeaways

The field of cortisol and bone health research has produced a remarkably consistent story across different research designs, different populations, different cortisol measurement methods, and different skeletal sites. Here is what the evidence firmly supports:

The Established Facts

1. Cortisol suppresses osteoblasts and activates osteoclasts through well-characterized molecular mechanisms, producing a net uncoupling of bone remodeling that favors bone loss.

1. Cortisol impairs calcium absorption by antagonizing vitamin D effects at the intestine and increasing renal calcium excretion, further compounding skeletal damage.

1. Even physiological variation in cortisol — within ranges seen in healthy elderly populations — is inversely associated with BMD at the lumbar spine and femoral neck, as demonstrated in multiple large cohort studies from 1999 to 2012.

1. Subclinical hypercortisolism affects 64–100% of individuals with increased cortisol levels in terms of impaired bone health, with vertebral fracture susceptibility that exceeds what standard DEXA would predict.

1. The 2025 Mendelian randomization study provides the strongest available causal evidence that mild cortisol excess is independently associated with osteoporosis risk at the lumbar spine.

1. Vertebral bodies and femoral neck are the most clinically significant sites of cortisol-related bone loss, corresponding to the highest fracture risk locations in older adults.

1. Bone loss from cortisol excess is at least partially reversible, particularly in terms of BMD, following successful treatment of the underlying cortisol source. Trabecular microarchitectural recovery is less certain.

1. Effective pharmacological strategies exist for protecting bone when cortisol cannot be fully normalized, including bisphosphonates, teriparatide, denosumab, and baseline calcium/vitamin D supplementation.

The Emerging Frontier

The most important developments in the field for the coming years include:

• Better detection of subclinical hypercortisolism in the large population of adults with adrenal incidentalomas, using standardized testing protocols and systematic bone health assessment
• High-resolution imaging (HR-pQCT, TBS — trabecular bone score) to capture the microarchitectural damage that DEXA misses
• Personalized fracture risk tools that incorporate cortisol status, not just standard clinical risk factors
• Understanding cortisol's role in psychosocial stress and bone loss — a pathway that may explain a portion of the socioeconomic gradient in fracture risk
• Sarcopenia as a mediating pathway — the 2025 MR study's finding that cortisol's effect on bone is partially mediated through muscle loss opens therapeutic opportunities targeting both muscle and bone simultaneously

A Final Word for Patients

If you have been told you have an adrenal incidentaloma, if you have been on long-term corticosteroid therapy, if you have a history of chronic stress with features suggesting HPA dysregulation, or if you have unexplained osteoporosis or vertebral fractures — cortisol testing should be part of your diagnostic workup. The science is clear enough to justify it. And if elevated cortisol is found, it is treatable, and its bone consequences can be meaningfully reduced.

---

Medical Disclaimer: This post is for educational purposes and summarizes published research findings. It is not a substitute for individualized medical advice. If you have concerns about cortisol levels or bone health, please consult a qualified endocrinologist or physician.

References and Further Reading:

• PMC10985775: Subclinical hypercortisolism and bone health (2024)
• Endocrine Reviews 39(5):519 — Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Glucocorticoid Exposure (updated 2026)
• PMC6011297: Effect of hypercortisolism on bone mineral density and bone quality
• PubMed: Cortisol secretion, bone health, and bone loss (2012)
• PubMed: Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women (2005)
• PubMed: Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men (1999)
• PubMed: Impact of mild cortisol excess on osteoporosis and the mediating role of sarcopenia-related traits — Mendelian randomization study (2025)